Literature DB >> 21994070

Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease.

Benedicte Ballanger1, Helene Klinger, Julien Eche, Jérôme Lerond, Anne-Evelyne Vallet, Didier Le Bars, Leon Tremblay, Véronique Sgambato-Faure, Emmanuel Broussolle, Stéphane Thobois.   

Abstract

Depression is frequent in Parkinson's disease, but its pathophysiology remains unclear. Two recent studies have investigated the role of serotonergic system at the presynaptic level. The objective of the present study was to use positron emission tomography and [(18)F]MPPF to investigate the role of postsynaptic serotonergic system dysfunction in the pathophysiology of depression in Parkinson's disease. Four parkinsonian patients with depression and 8 parkinsonian patients without depression were enrolled. Each patient underwent a scan using [(18)F]MPPF, a selective serotonin 1A receptor antagonist. Voxel-by-voxel statistical comparison of [(18)F]MPPF uptake of the 2 groups of parkinsonian patients and with 7 matched normal subjects was made using statistical parametric mapping (P uncorrected < .001). Compared with nondepressed parkinsonian patients, depressed patients exhibited reduced tracer uptake in the left hippocampus, the right insula, the left superior temporal cortex, and the orbitofrontal cortex. Compared with controls, nondepressed parkinsonian patients presented reduced [(18)F]MPPF uptake bilaterally in the inferior frontal cortex as well as in the right ventral striatum and insula. Compared with controls, [(18)F]MPPF uptake was decreased in depressed parkinsonian patients in the left dorsal anterior cingulate and orbitofrontal cortices, in the right hippocampic region, and in the temporal cortex. The present imaging study suggests that abnormalities in serotonin 1A receptor neurotransmission in the limbic system may be involved in the neural mechanisms underlying depression in patients with Parkinson's disease.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21994070     DOI: 10.1002/mds.23895

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  34 in total

1.  Cortical thinning in drug-naive Parkinson's disease patients with depression.

Authors:  ChunYan Luo; Wei Song; Qin Chen; Jing Yang; QiYong Gong; Hui-Fang Shang
Journal:  J Neurol       Date:  2016-08-02       Impact factor: 4.849

Review 2.  Synucleinopathies: common features and hippocampal manifestations.

Authors:  Weiwei Yang; Shun Yu
Journal:  Cell Mol Life Sci       Date:  2016-11-08       Impact factor: 9.261

Review 3.  Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson's Disease: Implication for Treatment.

Authors:  Stephane Thobois; Stephane Prange; Véronique Sgambato-Faure; Léon Tremblay; Emmanuel Broussolle
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-18       Impact factor: 5.081

Review 4.  Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues.

Authors:  Joseph Classen; Jiri Koschel; Christian Oehlwein; Klaus Seppi; Peter Urban; Christian Winkler; Ullrich Wüllner; Alexander Storch
Journal:  J Neural Transm (Vienna)       Date:  2017-07-12       Impact factor: 3.575

Review 5.  Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.

Authors:  Kentaro Hirao; Gregory M Pontone; Gwenn S Smith
Journal:  Neurosci Biobehav Rev       Date:  2014-11-20       Impact factor: 8.989

6.  Predicting targets of compounds against neurological diseases using cheminformatic methodology.

Authors:  Katarina Nikolic; Lazaros Mavridis; Oscar M Bautista-Aguilera; José Marco-Contelles; Holger Stark; Maria do Carmo Carreiras; Ilaria Rossi; Paola Massarelli; Danica Agbaba; Rona R Ramsay; John B O Mitchell
Journal:  J Comput Aided Mol Des       Date:  2014-11-26       Impact factor: 3.686

Review 7.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

8.  Effects of Agmatine on Depressive-Like Behavior Induced by Intracerebroventricular Administration of 1-Methyl-4-phenylpyridinium (MPP(+)).

Authors:  Morgana Moretti; Vivian Binder Neis; Filipe Carvalho Matheus; Mauricio Peña Cunha; Priscila Batista Rosa; Camille Mertins Ribeiro; Ana Lúcia S Rodrigues; Rui Daniel Prediger
Journal:  Neurotox Res       Date:  2015-07-09       Impact factor: 3.911

Review 9.  The serotonergic system in motor and non-motor manifestations of Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox
Journal:  Exp Brain Res       Date:  2013-06-28       Impact factor: 1.972

Review 10.  Uncovering the role of the insula in non-motor symptoms of Parkinson's disease.

Authors:  Leigh Christopher; Yuko Koshimori; Anthony E Lang; Marion Criaud; Antonio P Strafella
Journal:  Brain       Date:  2014-04-15       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.